Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/12/2025

Ceftriaxone Administration and Alternatives

Route of Administration

  • Ceftriaxone is administered exclusively by injection (IV or IM), as it is not absorbed adequately from the gastrointestinal tract when taken orally, according to the American Academy of Otolaryngology-Head and Neck Surgery 1, 2, 3, 4
  • The drug achieves complete absorption following IM administration, with peak plasma concentrations occurring 2-3 hours after injection, as reported by the American Academy of Otolaryngology-Head and Neck Surgery 1, 2, 3, 4

Oral Alternatives to Ceftriaxone

  • Cefixime 400 mg orally is the standard oral cephalosporin substitute for ceftriaxone in conditions like gonorrhea, recommended by the Centers for Disease Control and Prevention 5, 6, 7, 8
  • Cefixime has an antimicrobial spectrum similar to ceftriaxone, but provides lower and less sustained bactericidal levels than ceftriaxone 125 mg IM, according to the Centers for Disease Control and Prevention 5, 6, 7, 8

Key Clinical Considerations

  • The American Academy of Otolaryngology-Head and Neck Surgery recommends ceftriaxone for intravenous (IV) or intramuscular (IM) administration, without any mention of oral formulations 1, 2, 3, 4
  • The Centers for Disease Control and Prevention advises against confusing ceftriaxone with oral cephalosporins, and recommends prescribing cefixime or another appropriate oral cephalosporin instead 5, 6, 7, 8

Ceftriaxone Administration Guidelines

Clinical Recommendations

  • The Centers for Disease Control and Prevention (CDC) recommends cefixime 400 mg orally as an alternative to ceftriaxone for conditions like gonorrhea when oral therapy is appropriate, although cefixime provides lower and less sustained bactericidal levels compared to ceftriaxone 125 mg IM, making it less effective for serious infections 9
  • All clinical guidelines specify ceftriaxone for IV or IM use only, with no mention of oral formulations, as stated by the American Heart Association, based on guidelines from Circulation 10

Treatment Outcomes

  • Cefixime monotherapy has shown higher failure rates (5.8%) compared to ceftriaxone-based regimens (1.8%) for pharyngeal gonorrhea, according to the CDC 9

REFERENCES

1

antimicrobial treatment guidelines for acute bacterial rhinosinusitis. [LINK]

Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2004

2

antimicrobial treatment guidelines for acute bacterial rhinosinusitis. [LINK]

Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2004

3

antimicrobial treatment guidelines for acute bacterial rhinosinusitis. [LINK]

Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2004

4

antimicrobial treatment guidelines for acute bacterial rhinosinusitis. [LINK]

Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2004